Archive · 20 May 2025
Regeneron to Acquire Bankrupt 23andMe for $256 Million
23andMe, a company that helps people learn about their DNA, had financial problems and had to file for bankruptcy.
Regeneron, a company that does scientific research, is buying 23andMe for $256 million.
This means Regeneron will take control of 23andMe's data.
However, a separate part of 23andMe called Lemonaid Health will be shut down.
Regeneron plans to keep the genetic testing business going.
They promise to protect the privacy of people's data.
The deal is expected to be finalized in the third quarter of 2025.
Regeneron will acquire 23andMe for $256 million through a bankruptcy auction.
23andMe filed for Chapter 11 bankruptcy in March due to declining demand and a 2023 data breach.
Regeneron will honor 23andMe’s privacy commitments and adhere to legal safeguards for user data.
The acquisition excludes 23andMe's Lemonaid Health subsidiary, which will be shut down.
The transaction is expected to close by the third quarter of 2025.
- Who
- Regeneron is buying 23andMe.
- What
- Regeneron is acquiring 23andMe.
- When
- Transaction expected to close by the third quarter of 2025.
- Where
- Not explicitly mentioned.
- Why
- To obtain genetic data for research.
Potential Concerns
Company Response
Data Privacy
Potential Concerns
Some may worry about the privacy of their data and how it is handled.
Company Response
Regeneron said it will comply with 23andMe’s privacy policies and relevant laws when handling customer data.
- Buyer
- Regeneron Pharmaceuticals
- Seller
- 23andMe
- Purchase Price
- $256 million
- Bankruptcy Filing
- March
- Expected Closing
- Third Quarter 2025
- 23andMe Services
- DNA ancestry and health testing
